Price Performance & Valuation Year to date, GSK’s stock has gained 4.8% compared to the industry’s 20.0% growth. The stock has also underperformed the sector and the S&P 500.

GSK and S&P 500 Performance During 2007-08 Crisis GSK stock declined from $53 in September 2007 (pre-crisis peak) to around $28 in March 2009, as the markets bottomed out, implying it lost 48% of ...

GSK's native reporting currency is UK pounds, and shares are traded on the London Stock Exchange. GSK ADS, equivalent to 2 GSK shares, are traded on the NYSE in US$. The underlying performance of ...

GSK (NYSE:GSK), the $73bn market cap (at the time of writing), United Kingdom based Pharma giant announced its Q223 and H123 results today. The company's share price performance has been flat for ...

GSK GSK stock has risen 21.5% in the past six months. The consistently strong performance of the Specialty Medicines unit, regulatory and pipeline successes and an optimistic outlook for the long ...

Consequently, GSK will be exempted from these cases, alleviating the need for further pre-trial hearings. Also Read: GSK Upgrades Long-Term Outlook After Q4 Performance, Shingrix Vaccine And Newly ...

GSK plc (NYSE:GSK) is one of the most affordable yet financially rewarding healthcare stocks to buy right now, According to Insider Monkey’s database, 41 hedge funds are bullish on the stock ...

GSK is a Zacks Rank #3 (Hold) stock, with a Value Style Score of A and VGM Score of B. Shares are currently trading at a forward P/E of 9.2X for the current fiscal year compared to the Medical ...

The latest trading session saw GSK (GSK) ending at $36.19, denoting a -0.85% adjustment from its last day's close. The stock outperformed the S&P 500, which registered a daily loss of 1.47% ...

The investment community will be closely monitoring the performance of GSK in its forthcoming earnings report. The company is expected to report EPS of $0.95, up 5.56% from the prior-year quarter.